PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conference: World Federation of Hemophilia World Congress (Kuala Lumpur) - Presentation: Next Gen Protein Replacement Therapeutics: DNA-Encoded Protein (DPROT) Technology Demonstrates in vivo Production of Functional FVIII in Mouse Model
Date: Wednesday, April 22
Time: 9:45 AM MYT
- Poster Presentation: FVIII Expression Via Non-viral Vector DNA Medicine Platform Results in Efficacious Levels of FVIII Protein and Correction of the Bleeding Phenotype in Hemophilia A Mice
Date: Wednesday, April 22
Time: 10:45 AM MYT
Available abstracts will be shared on INOVIO's website following presentations. About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com. Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505, investor.relations@inovio.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-upcoming-scientific-conference-302731455.html
SOURCE INOVIO Pharmaceuticals, Inc. | 
